Advertisement

Topics

Kalytera Therapeutics, Inc. Company Profile

12:44 EDT 24th April 2018 | BioPortfolio

Kalytera Therapeutics, Inc. ("Kalytera") is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs. Kalytera is focused first on developing a new class of proprietary cannabidiol ("CBD") therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.


News Articles [726 Associated News Articles listed on BioPortfolio]

Kalytera to advance studies for graft-versus-host disease candidate

The US Patent and Trademark Office gave Kalytera Therapeutics a notice of allowance for its experimental drug using cannabidi -More- 

Kalytera scraps pre-clinical programs in bone disease

Kalytera Therapeutics has announced the termination of its pre-clinical development programs in the treatment of bone disease to focus its resources on graft versus host disease (GVHD) and pain progra...

Kalytera Therapeutics, Inc. Announces Closing of Brokered Private Placement

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. SAN FRANC...

Kalytera Retains Colwell Capital to Provide Investor Relations Services

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has retained Colwell Capital ("Colwell") to provide investor...

Kalytera Announces Grant of Stock Options

SAN FRANCISCO and TEL AVIV, Israel, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today announced that it has grante...

Kalytera Announces Settlement of Debt Transaction

SAN FRANCISCO and TEL AVIV, Israel, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today announced that it has entered into...

Kalytera Confirms No Material Change in Operations

SAN FRANCISCO and TEL AVIV, Israel, Dec. 05, 2017 (GLOBE NEWSWIRE) -- At the request of IIROC, Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") wishes to conf...

Kalytera Announces Next Issuance of Shares under Services Agreement with Salzman Group

SAN FRANCISCO and TEL AVIV, Israel, March 22, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today announced that the Compa...

PubMed Articles [411 Associated PubMed Articles listed on BioPortfolio]

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Introduction to Volume 1 of JOPT Special Issue.

Eyes on New Product Development: Preclinical Research.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [139 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1214 Associated Companies listed on BioPortfolio]

Kalytera Therapeutics, Inc.

Kalytera Therapeutics, Inc. ("Kalytera") is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise,...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Kalytera Therapeutics, Inc." on BioPortfolio

We have published hundreds of Kalytera Therapeutics, Inc. news stories on BioPortfolio along with dozens of Kalytera Therapeutics, Inc. Clinical Trials and PubMed Articles about Kalytera Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kalytera Therapeutics, Inc. Companies in our database. You can also find out about relevant Kalytera Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record